Literature DB >> 28237639

Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis.

Carsten Hjorthøj1, Anne Emilie Stürup2, John J McGrath3, Merete Nordentoft4.   

Abstract

BACKGROUND: Several studies and meta-analyses have shown that mortality in people with schizophrenia is higher than that in the general population but have used relative measures, such as standardised mortality ratios. We did a systematic review and meta-analysis to estimate years of potential life lost and life expectancy in schizophrenia, which are more direct, absolute measures of increased mortality.
METHODS: We searched MEDLINE, PsycINFO, Embase, Cinahl, and Web of Science for published studies on years of potential life lost and life expectancy in schizophrenia. Data from individual studies were combined in meta-analyses as weighted averages. We did subgroup analyses for sex, geographical region, timing of publication, and risk of bias (estimated with the Newcastle-Ottawa Scale).
FINDINGS: We identified 11 studies in 13 publications covering all inhabited continents except South America (Africa n=1, Asia n=1, Australia n=1, Europe n=7, and North America n=3) that involved up to 247 603 patients. Schizophrenia was associated with a weighted average of 14·5 years of potential life lost (95% CI 11·2-17·8), and was higher for men than women (15·9, 13·8-18·0 vs 13·6, 11·4-15·8). Loss was least in the Asian study and greatest in Africa. The overall weighted average life expectancy was 64·7 years (95% CI 61·1-71·3), and was lower for men than women (59·9 years, 95% CI 55·5-64·3 vs 67·6 years, 63·1-72·1). Life expectancy was lowest in Asia and Africa. Timing of publication and risk of bias had little effect on results.
INTERPRETATION: The effects of schizophrenia on years potential life lost and life expectancy seem to be substantial and not to have lessened over time. Development and implementation of interventions and initiatives to reduce this mortality gap are urgently needed. FUNDING: None.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28237639     DOI: 10.1016/S2215-0366(17)30078-0

Source DB:  PubMed          Journal:  Lancet Psychiatry        ISSN: 2215-0366            Impact factor:   27.083


  206 in total

1.  Sedentary Behavior and Quality of Life in People with Psychotic Disorders from a Low Income Country: A Study from Uganda.

Authors:  Davy Vancampfort; Michel Probst; Simon Rosenbaum; Philip B Ward; Tine Van Damme; James Mugisha
Journal:  Community Ment Health J       Date:  2018-12-05

2.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

3.  Avoidance of accelerated aging in schizophrenia?: Clinical and biological characterization of an exceptionally high functioning individual.

Authors:  Barton W Palmer; Raeanne C Moore; Lisa T Eyler; Luz L Pinto; Elyn R Saks; Dilip V Jeste
Journal:  Schizophr Res       Date:  2017-08-08       Impact factor: 4.939

Review 4.  Management of Cardiovascular Health in People with Severe Mental Disorders.

Authors:  Cédric Lemogne; Jacques Blacher; Guillaume Airagnes; Nicolas Hoertel; Sébastien Czernichow; Nicolas Danchin; Pierre Meneton; Frédéric Limosin; Jess G Fiedorowicz
Journal:  Curr Cardiol Rep       Date:  2021-01-06       Impact factor: 2.931

5.  Physical activity of people with mental disorders compared to the general population: a systematic review of longitudinal cohort studies.

Authors:  Shuichi Suetani; Brendon Stubbs; John J McGrath; James G Scott
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-08-23       Impact factor: 4.328

6.  [The CIMH track concept in the treatment of psychotic disorders].

Authors:  Dusan Hirjak; Peter Gass; Michael Deuschle; F Markus Leweke; Andreas Böhringer; Nadine Schenkel; Doris Borgwedel; Marco Heser; Antje Breisacher; Andreas Meyer-Lindenberg
Journal:  Nervenarzt       Date:  2020-03       Impact factor: 1.214

7.  20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20).

Authors:  Heidi Taipale; Antti Tanskanen; Juha Mehtälä; Pia Vattulainen; Christoph U Correll; Jari Tiihonen
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

8.  Predictors of study drop-out and service disengagement in patients at clinical high risk for psychosis.

Authors:  Letizia Leanza; Erich Studerus; Amatya J Mackintosh; Katharina Beck; Leonie Seiler; Christina Andreou; Anita Riecher-Rössler
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-10-23       Impact factor: 4.328

9.  The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials.

Authors:  Davy Vancampfort; Joseph Firth; Christoph U Correll; Marco Solmi; Dan Siskind; Marc De Hert; Rebekah Carney; Ai Koyanagi; André F Carvalho; Fiona Gaughran; Brendon Stubbs
Journal:  World Psychiatry       Date:  2019-02       Impact factor: 49.548

Review 10.  Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016.

Authors:  Fiona J Charlson; Alize J Ferrari; Damian F Santomauro; Sandra Diminic; Emily Stockings; James G Scott; John J McGrath; Harvey A Whiteford
Journal:  Schizophr Bull       Date:  2018-10-17       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.